The Medicine & Healthcare products Regulatory Agency (MHRA) has approved the first licensed low-dose atropine (LDA) treatment for slowing the progression of childhood myopia.
The virtual Hospital Eye Service experience replaces the in-person experience pre-registration trainees would normally have gained in a hospital setting.